SutroVax nets $22M Series A for conjugate vaccine work
Bay Area startup SutroVax just raised $22 million for work in developing conjugate vaccines - and likely improving upon existing inoculations for pneumococcal conditions.
Bay Area startup SutroVax just raised $22 million for work in developing conjugate vaccines - and likely improving upon existing inoculations for pneumococcal conditions.